A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
According to Smith's account, "each one, quietly but firmly, without hesitation, said: 'Yes'." At 11:00 local time on 11 November 1965, Armistice Day, during the traditional two minutes' silence to remember the fallen of the two World Wars, Smith declared Rhodesia independent and signed the proclamation document, with Dupont and the other 10 ministers of the Cabinet following. The timing was intended to emphasise the sacrifices Rhodesia had made for Britain in wartime. As Ken Flower later said, "the rebellion was made to appear as though it was not a rebellion". Smith and his ministers still pledged allegiance to Queen Elizabeth II, whose official portrait hung prominently behind them as they signed; the declaration even ended "God Save The Queen". Four junior members of the Cabinet—Lance Smith, Ian Dillon, Andrew Dunlop and P. K. van der Byl—did not sign, but were included in the official photograph.
== Morphology == An animal's hump is formed by neural spines on the thoracic vertebrae. Despite only being known from the fossil record, the woolly mammoth and species of the genus Titanotylopus are assumed to have had humps due to the presence of such spines in their skeletons. In the gaur, the hump is formed solely because of the skeletal structure, as its third to eleventh vertebrae have such spines. In both dromedaries and bactrian camels, humps are attached to the adipose tissue in the dorsal region, and fixed in place by the trapezius and rhomboid muscles.
==== Effects ==== In contrast to amphetamines like (–)-cathinone, but similarly to mescaline, DOM has shown no stimulant-like or reinforcing effects in rhesus monkeys. Conversely however, DOC has shown reinforcing effects, including conditioned place preference (CPP) and self-administration, in rodents similarly to methamphetamine. This is analogous to other findings in which various 2C and NBOMe drugs have been found to produce brain dopaminergic elevations and reinforcing effects in rodents.
Sources: en.wikipedia.org
Reprocessing methods have reduced emissions since then, but as of 2005 the primary release of technetium-99 into the environment is by the Sellafield plant, which released an estimated 550 TBq (about 900 kg) from 1995 to 1999 into the Irish Sea. From 2000 onwards the amount has been limited by regulation to 90 TBq (about 140 kg) per year. Discharge of technetium into the sea resulted in contamination of some seafood with minuscule quantities of this element. For example, European lobster and fish from west Cumbria contain about 1 Bq/kg of technetium.
=== Pharmacokinetics === Insulin degludec has an onset of action of 30–90 minutes (similar to insulin glargine and insulin detemir). There is no peak in activity, due to the slow release into systemic circulation. The duration of action of insulin degludec is reported as being longer than 24 hours. Because the half-life is longer than 24 hours, it is approved for daily dosing at any time each day - as long as more than 8 hours has elapsed since the previous dose. A missed dose is advised to be taken as soon as remembered, then return to a normal schedule.
In July 2009, Mohammad Sajjadur Rahman noted that Russia's role in the Caucasus region in the 1990s "transformed the separatist conflicts into a dispute between Georgia and Russia" and that "Realism, the most dominant theory of International Relations, can be applied in analyzing Russian behavior" in the conflict which was the first Russian military action since the Soviet–Afghan War. Rahman denied the claim that Russia was defending itself, explaining that "long before the war broke out, Russia had established the infrastructure and logistical support for a military invasion" and decision to go to war was "guided by a number of geopolitical interests that Russia sought to advance through a decisive victory", such as "Putins’ evident desire to elevate Russia's Great Power image". However, "the war exposed Russia's failure to accomplish political objectives without recourse to violence." Rahman summarized that "the causes of the August war were indeed complex and multifaceted" and the failure of the West "in deescalating the tension also contributed to the outbreak of this limited war."
=== Altered platelet function === Congenital Disorders of adhesion Bernard–Soulier syndrome Disorders of activation Disorders of granule amount or release Hermansky–Pudlak syndrome Gray platelet syndrome ADP receptor defect Decreased cyclooxygenase activity Platelet storage pool deficiency Disorders of aggregation Glanzmann's thrombasthenia Wiskott–Aldrich syndrome Disorders of coagulant activity COAT platelet defect Scott syndrome Acquired Disorders of adhesion Paroxysmal nocturnal hemoglobinuria Asthma Aspirin-exacerbated respiratory disease (AERD/Samter's triad) Cancer Malaria Decreased cyclooxygenase activity
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.